tradmap

AUTL Autolus Therapeutics plc

$1.50 -1.31%

Healthcare · Biological Products, (No Diagnostic Substances)

Autolus Therapeutics plc (AUTL) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry. Shares last traded at $1.50, 46.1% below their 52-week high. Over the past year the stock is down 25.7%. Net profit margin is -381.4%, below the peer median of 6.3%. Revenue grew 644.9% year over year.

Market Cap
Shares Out
EPS (TTM)
$-1.71
P/E Ratio
P/S Ratio
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$2.79
52-Week Low
$1.18
Volume
68,480
Avg Vol (3m)
80,587.079

Performance

1W
-4.14%
1M
-7.38%
3M
+5.24%
6M
-5.94%
YTD
-20.16%
1Y
-25.68%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
44.54
SMA (50)
$1.58
SMA (200)
$1.53
Price vs SMA50
-5.00%
Price vs SMA200
-1.55%
ATR (14)
$0.12

Financials

Revenue
$75M
Net Income
$-288M
Gross Margin
Operating Margin
-358.9%
Net Margin
-381.4%
Return on Equity
-264.2%
Return on Assets
-54.6%
Current Ratio
5.80
Debt / Equity
0.00
Revenue Growth (YoY)
+644.9%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.27 2026-05-14
FY 2025 $-1.08 2026-03-27
Q3 2025 $-0.74 2025-11-12
Q2 2025 $-0.44 2025-08-12
Q1 2026 $-0.26 2026-05-14
FY 2025 $-0.86 2026-03-27

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

AUTL vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.